Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting

GO BACK TO PRESS RELEASES & MEDIA Press Release April 28, 2025 Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting CLSP-1025, Clasp’s first-in-class T-cell engager (TCE) targeting mutant p53, demonstrates potent preclinical activity with a favorable pharmacokinetic and safety profile, supporting its transition into clinical studies CLSP-1025 is under evaluation in the GUARDIAN-101 trial — the first clinical investigation of a TCE targeting an oncogenic driver mutation CAMBRIDGE, MA and ROCKVILLE, MD – April 28